641 related articles for article (PubMed ID: 15626944)
1. Caspofungin therapy of neonates with invasive candidiasis.
Odio CM; Araya R; Pinto LE; Castro CE; Vasquez S; Alfaro B; Sàenz A; Herrera ML; Walsh TJ
Pediatr Infect Dis J; 2004 Dec; 23(12):1093-7. PubMed ID: 15626944
[TBL] [Abstract][Full Text] [Related]
2. Successful treatment of an infant infected with refractory C. parapsilosis with caspofungin.
Ozkaya-Parlakay A; Tezer H; Kazmacan T; Gulhan B; Unal S
J Trop Pediatr; 2014 Aug; 60(4):329-30. PubMed ID: 24567311
[TBL] [Abstract][Full Text] [Related]
3. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
4. Experience with caspofungin in the treatment of persistent fungemia in neonates.
Natarajan G; Lulic-Botica M; Rongkavilit C; Pappas A; Bedard M
J Perinatol; 2005 Dec; 25(12):770-7. PubMed ID: 16222348
[TBL] [Abstract][Full Text] [Related]
5. Caspofungin: a review of its use in the treatment of fungal infections.
McCormack PL; Perry CM
Drugs; 2005; 65(14):2049-68. PubMed ID: 16162025
[TBL] [Abstract][Full Text] [Related]
6. Invasive candidiasis in cancer patients: observations from a randomized clinical trial.
DiNubile MJ; Hille D; Sable CA; Kartsonis NA
J Infect; 2005 Jun; 50(5):443-9. PubMed ID: 15907554
[TBL] [Abstract][Full Text] [Related]
7. Caspofungin for the treatment of azole resistant candidemia in a premature infant.
Smith PB; Steinbach WJ; Cotten CM; Schell WA; Perfect JR; Walsh TJ; Benjamin DK
J Perinatol; 2007 Feb; 27(2):127-9. PubMed ID: 17262048
[TBL] [Abstract][Full Text] [Related]
8. In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance.
Pfaller MA; Boyken L; Hollis RJ; Messer SA; Tendolkar S; Diekema DJ
J Clin Microbiol; 2006 Mar; 44(3):760-3. PubMed ID: 16517851
[TBL] [Abstract][Full Text] [Related]
9. Successful caspofungin treatment of multidrug resistant Candida parapsilosis septicaemia in an extremely low birth weight neonate.
Yalaz M; Akisu M; Hilmioglu S; Calkavur S; Cakmak B; Kultursay N
Mycoses; 2006 May; 49(3):242-5. PubMed ID: 16681818
[TBL] [Abstract][Full Text] [Related]
10. Caspofungin use in patients with invasive candidiasis caused by common non-albicans Candida species: review of the caspofungin database.
Colombo AL; Ngai AL; Bourque M; Bradshaw SK; Strohmaier KM; Taylor AF; Lupinacci RJ; Kartsonis NA
Antimicrob Agents Chemother; 2010 May; 54(5):1864-71. PubMed ID: 20231388
[TBL] [Abstract][Full Text] [Related]
11. Global distribution and outcomes for Candida species causing invasive candidiasis: results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis.
Colombo AL; Perfect J; DiNubile M; Bartizal K; Motyl M; Hicks P; Lupinacci R; Sable C; Kartsonis N
Eur J Clin Microbiol Infect Dis; 2003 Aug; 22(8):470-4. PubMed ID: 12884068
[TBL] [Abstract][Full Text] [Related]
12. The patterns of colonization and antifungal susceptibility of Candida, isolated from preterm neonates in Khorramabad, South West of Iran.
Kooshki P; Rezaei-Matehkolaei A; Mahmoudabadi AZ
J Mycol Med; 2018 Jun; 28(2):340-344. PubMed ID: 29530715
[TBL] [Abstract][Full Text] [Related]
13. Comparison of caspofungin and amphotericin B for invasive candidiasis.
Mora-Duarte J; Betts R; Rotstein C; Colombo AL; Thompson-Moya L; Smietana J; Lupinacci R; Sable C; Kartsonis N; Perfect J;
N Engl J Med; 2002 Dec; 347(25):2020-9. PubMed ID: 12490683
[TBL] [Abstract][Full Text] [Related]
14. Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin.
Olson JA; Adler-Moore JP; Smith PJ; Proffitt RT
Antimicrob Agents Chemother; 2005 Dec; 49(12):4895-902. PubMed ID: 16304150
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of caspofungin in invasive candidiasis and candidemia--de-escalation strategy.
Lichtenstern C; Nguyen TH; Schemmer P; Hoppe-Tichy T; Weigand MA
Mycoses; 2008; 51 Suppl 1():35-46. PubMed ID: 18471160
[TBL] [Abstract][Full Text] [Related]
16. Caspofungin: a review of its use in oesophageal candidiasis, invasive candidiasis and invasive aspergillosis.
Keating G; Figgitt D
Drugs; 2003; 63(20):2235-63. PubMed ID: 14498760
[TBL] [Abstract][Full Text] [Related]
17. Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy.
Hakki M; Staab JF; Marr KA
Antimicrob Agents Chemother; 2006 Jul; 50(7):2522-4. PubMed ID: 16801435
[TBL] [Abstract][Full Text] [Related]
18. [Successful treatment with caspofungin of an invasive candidosis resistant to liposomal amphotericin B in a neutropenic patient].
Rome A; André N; Michel A; Coze C; Gentet JC; Bernard JL
Arch Pediatr; 2006 Dec; 13(12):1556-7. PubMed ID: 17049216
[No Abstract] [Full Text] [Related]
19. Antifungal susceptibilities of Candida glabrata species complex, Candida krusei, Candida parapsilosis species complex and Candida tropicalis causing invasive candidiasis in China: 3 year national surveillance.
Xiao M; Fan X; Chen SC; Wang H; Sun ZY; Liao K; Chen SL; Yan Y; Kang M; Hu ZD; Chu YZ; Hu TS; Ni YX; Zou GL; Kong F; Xu YC
J Antimicrob Chemother; 2015 Mar; 70(3):802-10. PubMed ID: 25473027
[TBL] [Abstract][Full Text] [Related]
20. [Treatment with caspofungin of Candida tropicalis endocarditis resistant to fluconazol].
del Castillo M; Wainsztein N; Klein F; Manganello S; Orellana N
Medicina (B Aires); 2004; 64(2):152-4. PubMed ID: 15628305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]